Dashboard
Financial statements
AMGN

Company financials

Amgen

Health Care Biotechnology Thousand Oaks, California Last filing Feb 13, 2026 · FY2025
Revenue FY2025
$36.8B
3y CAGR +11.8% P83
Net income FY2025
$7.7B
Net margin +21.0% P80
Total assets FY2025
$90.6B
ROA +8.5% P68
Operating cash flow FY2025
$10.0B
FCF margin +22.0% P82
19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

27 accounts · 10 years
Total assets $90.6B
Total liabilities $25.5B
Shareholders equity $8.7B
Account 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Trend
Assets
Cash and Cash Equivalents 24.8% 35.8% 38.8% 29.0% 30.8% 24.6% 25.8% 29.2% 16.6% 14.1%
Short Term Investments 0.0% 0.0% 0.0% 6.4% 0.2% 17.2% 12.3% 94.2% 165.8% 151.6%
Accounts Receivable 26.0% 20.3% 25.8% 21.1% 18.8% 17.8% 17.4% 15.1% 14.2% 13.8%
Inventory 16.9% 20.9% 33.8% 18.7% 15.7% 15.3% 15.3% 12.4% 12.4% 11.9%
Prepaid Expenses 11.2% 9.8% 9.2% 9.1% 9.1% 8.2% 8.1% 7.6% 7.6% 8.8%
Other Current Assets 11.2% 9.8% 9.2% 9.1% 9.1% 8.2% 8.1% 7.6% 7.6% 8.8%
Total Current Assets 79.1% 86.9% 107.6% 84.3% 74.6% 83.2% 78.9% 158.4% 216.5% 200.1%
Property,Plant and Equipment 21.5% 19.6% 21.1% 20.6% 20.0% 19.2% 21.1% 20.9% 21.8% 21.6%
Goodwill 50.8% 55.8% 66.1% 59.0% 57.3% 57.8% 62.9% 61.9% 64.6% 64.2%
Intangible Assets 60.6% 82.9% 115.8% 61.1% 58.4% 65.2% 83.1% 31.3% 37.7% 44.7%
Other Noncurrent Assets 34.4% 29.7% 34.1% 22.4% 25.1% 22.2% 9.5% 7.2% 9.3% 7.1%
Total Assets 246.5% 274.8% 344.6% 247.4% 235.4% 247.6% 255.6% 279.7% 349.9% 337.6%
Liabilities
Accounts Payable 6.4% 5.7% 5.6% 6.0% 5.3% 5.6% 5.9% 5.1% 5.9% 4.0%
Accrued Liabilities 50.4% 52.8% 54.5% 47.6% 41.3% 39.9% 36.4% 33.1% 28.5% 25.6%
Current Portion of Long Term Debt 12.5% 10.6% 5.1% 6.0% 0.3% 0.4% 12.6% 18.6% 5.0% 19.2%
Other Current Liabilities 6.5% 7.0% 8.3% 10.1% 9.5% 8.0% 6.9% 5.4% 5.4% 6.5%
Total Current Liabilities 69.4% 69.1% 65.2% 59.6% 46.9% 45.8% 54.9% 56.8% 39.5% 48.7%
Long Term Debt 136.1% 169.2% 224.1% 141.9% 127.9% 129.4% 115.4% 124.3% 149.6% 131.3%
Deferred Tax Liabilities 3.7% 4.8% 8.4% 7.1% 5.6% 6.0% 7.6% 8.3% 9.5% 16.5%
Other Noncurrent Liabilities 6.5% 7.0% 8.3% 10.1% 9.5% 8.0% 6.9% 5.4% 5.4% 6.5%
Total Liabilities 69.4% 69.1% 65.2% 59.6% 46.9% 45.8% 54.9% 56.8% 39.5% 48.7%
Equity
Preferred Stock 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Common Stock 8.9% 9.8% 11.7% 12.5% 12.7% 13.1% 14.3% 14.2% 15.2% 15.2%
Retained Earnings -68.3% -82.5% -94.2% -108.7% -94.7% -84.2% -91.3% -75.7% -22.2% -1.9%
Accumulated Other Comprehensive Income -0.7% -0.2% -1.0% -0.9% -3.1% -3.9% -2.3% -3.2% -3.0% -2.0%
Total Stockholders Equity 23.6% 17.6% 22.1% 13.9% 25.8% 37.0% 41.4% 52.6% 110.5% 129.9%
Total Liabilitiesand Equity 246.5% 274.8% 344.6% 247.4% 235.4% 247.6% 255.6% 279.7% 349.9% 337.6%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 10 years
Ratio 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Profitability
Gross margin +67.2% +61.5% +70.0% +75.7% +75.2% +75.8% +81.4% +82.7% +82.2% +81.9%
Operating margin +24.7% +21.7% +28.0% +36.3% +29.4% +35.9% +41.4% +43.2% +43.6% +42.6%
Net margin +21.0% +12.2% +23.8% +24.9% +22.7% +28.6% +33.6% +35.3% +8.7% +33.6%
FCF margin +22.0% +31.1% +26.1% +33.4% +32.3% +38.9% +36.5% +44.5% +46.0% +41.8%
Growth
Revenue CAGR (3y) +11.8% +8.8% +3.5% +4.1% +3.0% +3.6% +0.5% +3.1% +4.4% +7.2%
Returns
ROE +89.1% +69.6% +107.8% +179.0% +88.0% +77.2% +81.1% +67.2% +7.8% +25.8%
ROA +8.5% +4.5% +6.9% +10.1% +9.6% +11.5% +13.1% +12.6% +2.5% +9.9%
ROIC +14.4% +11.9% +11.3% +24.4% +21.0% +22.6% +24.8% +22.9% +3.6% +13.5%
Liquidity
Current ratio 1.14x 1.26x 1.65x 1.41x 1.59x 1.81x 1.44x 2.79x 5.49x 4.11x
Quick ratio 0.73x 0.81x 0.99x 0.84x 1.06x 0.93x 0.79x 0.78x 0.78x 0.57x
Leverage
D/E 2.94x 3.93x 2.95x 4.28x 1.82x 1.24x 1.33x 1.08x 0.36x 0.38x
Interest coverage 3.30x 2.30x 2.75x 6.80x 6.38x 7.24x 7.51x 7.37x 7.65x 7.77x
Efficiency
Asset turnover 0.41x 0.36x 0.29x 0.40x 0.42x 0.40x 0.39x 0.36x 0.29x 0.30x
Cash conversion cycle +212d +219d +437d +268d +223d +211d +249d +209d +185d +211d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched
Saving notes adds AMGN to your watchlist.